<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Fine-Tuning ChemBERTa for Predicting Inhibitory Activity Against TDP1 Using Deep Learning - Health AI Hub</title>
    <meta name="description" content="This paper introduces a deep learning framework that utilizes fine-tuned ChemBERTa, a pre-trained chemical language model, to predict the pIC50 values of small ">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Fine-Tuning ChemBERTa for Predicting Inhibitory Activity Against TDP1 Using Deep Learning</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.04252v1" target="_blank">2512.04252v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-03
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Baichuan Zeng
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, cs.AI
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.04252v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.04252v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces a deep learning framework that utilizes fine-tuned ChemBERTa, a pre-trained chemical language model, to predict the pIC50 values of small molecules against Tyrosyl-DNA Phosphodiesterase 1 (TDP1) directly from SMILES strings. Leveraging a large, imbalanced dataset and advanced pre-training strategies, the developed model significantly outperforms classical baselines and demonstrates competitive performance with Random Forest for identifying potential TDP1 inhibitors. This robust, 3D-structure-free tool aims to accelerate early drug discovery for overcoming cancer chemoresistance.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>TDP1 is a crucial enzymatic target involved in DNA repair, and its inhibition is a promising strategy to overcome cancer chemoresistance, thereby enhancing the efficacy of existing chemotherapy. Accurate prediction of TDP1 inhibitors can significantly accelerate the development of novel adjunct therapies for cancer treatment.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The AI application described is a deep learning framework (fine-tuned ChemBERTa) that quantitatively predicts the inhibitory potency (pIC50) of small molecules against Tyrosyl-DNA Phosphodiesterase 1 (TDP1) directly from their SMILES strings. This serves as a computational tool to accelerate early drug discovery for cancer by prioritizing promising TDP1 inhibitors for experimental testing, thereby streamlining the development of new treatments for overcoming cancer chemoresistance.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses the critical challenge of predicting inhibitory potency against TDP1, a key target for overcoming cancer chemoresistance in early drug discovery.</li>
                    
                    <li>Employs fine-tuned variants of ChemBERTa, a pre-trained chemical language model, for quantitative regression of pIC50 values directly from molecular SMILES strings.</li>
                    
                    <li>Leverages a large-scale consensus dataset of 177,092 compounds, meticulously addressing severe activity imbalance (only 2.1% active) through stratified data splits and sample weighting.</li>
                    
                    <li>Systematically evaluates two pre-training strategies: Masked Language Modeling (MLM) and Masked Token Regression (MTR) for optimal performance.</li>
                    
                    <li>Achieves superior performance compared to classical baselines (e.g., Random Predictor) in both regression accuracy and virtual screening utility.</li>
                    
                    <li>Demonstrates competitive performance against Random Forest, achieving a high enrichment factor (EF@1% 17.4) and precision (Precision@1% 37.4) among top-ranked predictions.</li>
                    
                    <li>Provides a robust and ready-to-deploy computational tool for accelerating target-specific drug discovery by prioritizing TDP1 inhibitors for experimental testing without requiring 3D structural information.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study utilized deep learning with fine-tuned ChemBERTa, a pre-trained chemical language model, for quantitative regression of pIC50 values. Input features were Simplified Molecular Input Line Entry System (SMILES) strings, eliminating the need for 3D molecular structures. The model was trained on a large consensus dataset of 177,092 compounds. To handle severe activity imbalance (2.1% active), stratified data splits and sample weighting were employed. Two pre-training strategies, Masked Language Modeling (MLM) and Masked Token Regression (MTR), were systematically evaluated. Model performance was assessed against classical baselines (Random Predictor) and Random Forest using metrics like regression accuracy, enrichment factor (EF@1%), and precision (Precision@1%).</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The fine-tuned ChemBERTa model significantly outperformed classical baselines in both regression accuracy and virtual screening utility. It achieved competitive performance compared to Random Forest, demonstrating a high enrichment factor EF@1% of 17.4 and a precision Precision@1% of 37.4 among the top 1% of predictions. The model provides accurate, 3D-structure-free pIC50 predictions directly from SMILES, validated through rigorous ablation and hyperparameter studies, proving its robustness.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This computational tool offers a rapid and cost-effective method for identifying and prioritizing potential TDP1 inhibitors, directly impacting the early stages of drug discovery for cancer. By efficiently filtering vast chemical spaces, it can significantly reduce the experimental burden, accelerate the development pipeline for anti-cancer therapies, and ultimately lead to new drugs that combat chemoresistance.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state any specific limitations of the developed model or the study.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The abstract does not explicitly mention future research directions, but the work implies further applications and advancements of chemical transformers in target-specific drug discovery and chemical property prediction.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                    <span class="tag">Drug Discovery</span>
                    
                    <span class="tag">Cancer Therapy</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Deep Learning</span>
                    
                    <span class="tag tag-keyword">ChemBERTa</span>
                    
                    <span class="tag tag-keyword">TDP1 Inhibitors</span>
                    
                    <span class="tag tag-keyword">pIC50 Prediction</span>
                    
                    <span class="tag tag-keyword">Drug Discovery</span>
                    
                    <span class="tag tag-keyword">Cancer Chemoresistance</span>
                    
                    <span class="tag tag-keyword">SMILES</span>
                    
                    <span class="tag tag-keyword">Virtual Screening</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Predicting the inhibitory potency of small molecules against Tyrosyl-DNA Phosphodiesterase 1 (TDP1)-a key target in overcoming cancer chemoresistance-remains a critical challenge in early drug discovery. We present a deep learning framework for the quantitative regression of pIC50 values from molecular Simplified Molecular Input Line Entry System (SMILES) strings using fine-tuned variants of ChemBERTa, a pre-trained chemical language model. Leveraging a large-scale consensus dataset of 177,092 compounds, we systematically evaluate two pre-training strategies-Masked Language Modeling (MLM) and Masked Token Regression (MTR)-under stratified data splits and sample weighting to address severe activity imbalance which only 2.1% are active. Our approach outperforms classical baselines Random Predictor in both regression accuracy and virtual screening utility, and has competitive performance compared to Random Forest, achieving high enrichment factor EF@1% 17.4 and precision Precision@1% 37.4 among top-ranked predictions. The resulting model, validated through rigorous ablation and hyperparameter studies, provides a robust, ready-to-deploy tool for prioritizing TDP1 inhibitors for experimental testing. By enabling accurate, 3D-structure-free pIC50 prediction directly from SMILES, this work demonstrates the transformative potential of chemical transformers in accelerating target-specific drug discovery.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>